NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

TherapeuticsMD, Inc. Common Stock (TXMD) Stock Analysis

TherapeuticsMD, Inc. Common Stock (TXMD) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

TXMD

$2.21

−$0.03 (−1.34%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TXMD with… →

TXMD Key Statistics

As of Sep 4, 2026
Trading
Open
$2.23
Previous Close
$2.24
Day's Range
2.18–2.23
52-Week Range
0.99–2.95
Volume
7.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$25.58M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.82
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.03
Financials (FY)
Revenue (FY)
$3.02M+71.61%
Net Income (FY)
−$569.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.57M
1-Year Return
+104.63%
Dividend and dates
Avg Volume
38.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TXMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+35.58%
2025+89.53%
2024−61.78%
2023−59.75%
2022−68.94%
2021−70.25%
2020−50.00%
2019−36.48%
2018−36.92%
2017+4.68%
2016 (partial year)−26.59%

As of September 4, 2026.

TXMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.02M−$569.00K−18.8%
2024$1.76M−$2.18M−123.9%
2023$1.30M−$10.28M−789.4%
2022$69.96M$112.00M160.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.02M—−$4.21M−$569.00K−18.8%
2024$1.76M—−$4.84M−$2.18M−123.9%
2023$1.30M$1.30M−$8.52M−$10.28M−789.4%
2022$69.96M$68.57M$10.66M$112.00M160.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TXMD Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricTXMDDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio7.822.303.4x the median
Profit margin−6.64%−3.14%3.5 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TherapeuticsMD, Inc. Common Stock (TXMD) is capitalised at $25.58M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 1.

The most recent close on file for TXMD is $2.21, dated September 4, 2026. That is −$0.03 (−1.34%) against the previous close. Over the past 52 weeks the price has ranged from $0.99 to $2.95. The latest close sits 123.23% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.02M. Against the prior fiscal year total of $1.76M, that is a change of +71.61%. The same year closed with a net loss of $569.00K. The reported profit margin is −6.64%. That is 3.5 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.03.

Across the 4 fiscal years on file, revenue moves from $69.96M in 2022 to $3.02M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 6.31. Measured against sales, the shares trade at 7.82 times revenue. On price-to-sales that is 3.4 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.65. Annualized volatility over the trailing 10 years is 146.02%. The trailing one-year price return is +104.63%. Across 10 years the annualized return works out at −39.73%.

Growth & Income

No dividend is on file for TXMD.

The strongest complete calendar year on file is 2025 at +89.53%; the weakest is 2021 at −70.25%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is +35.58%.

Peer Comparison

TherapeuticsMD, Inc. Common Stock (TXMD) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TherapeuticsMD, Inc. Common Stock TXMD $25.58M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. TherapeuticsMD, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TherapeuticsMD, Inc. Common Stock

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Visit website →